Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. - Wikidata - awgldk - TriplyDB

Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.

Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.

http://www.wikidata.org/entity/Q34623515

about

Recent Advances in Antiviral Therapy for Chronic Hepatitis C Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life Sofosbuvir, a Significant Paradigm Change in HCV Treatment Impact of new treatment options for hepatitis C virus infection in liver transplantation Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance New era for management of chronic hepatitis C virus using direct antiviral agents: A review Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential Synthesis of nucleoside phosphate and phosphonate prodrugs Chutes and ladders in hepatitis C nucleoside drug development Prodrugs of phosphonates and phosphates: crossing the membrane barrier Changing the face of hepatitis C management - the design and development of sofosbuvir Spatiotemporal analysis of hepatitis C virus infection Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase The FDA-approved drug sofosbuvir inhibits Zika virus infection Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase.Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase A liquid chromatography-tandem mass spectrometry method for the quantitative determination of diastereomers of a phosphoramidate nucleotide prodrug (PSI-7851) in human plasma.A cutting-edge view on the current state of antiviral drug development.Direct-acting antiviral agents for hepatitis C virus infection.Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection.Substrates and Inhibitors of SAMHD1.Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine.Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661.Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.Novel and sensitive UPLC-MS/MS method for quantification of sofosbuvir in human plasma: application to a bioequivalence study.Thiophene-expanded guanosine analogues of Gemcitabine.Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs A multifunctional catalyst that stereoselectively assembles prodrugs.Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system.Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability.Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection.Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects.Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection.

P2860

Q26750476-3C331069-3427-4A0F-B821-8A3DFC99D432 Q26750628-03E86A28-4E1C-4870-AB86-67D3E7D26B8A Q26781773-4B91B708-C85A-44FC-9BC1-4753282F604C Q26782017-E8F28332-4011-4426-A7DE-049C53DC2ED9 Q26783056-9247431C-313C-428B-8AE1-F8BA80F0C4AF Q26800050-851A3297-A7BD-4532-A35F-22DC5E2532D9 Q26827322-93631C12-9089-4831-ABEC-92702726011C Q26865400-6FFEE43A-6E4E-41AF-9BB2-E2228EA295C4 Q26998630-DCC6BECC-9A57-4531-B2CA-BD648C801529 Q27005712-D634FBE5-FCB1-4782-B852-65AC36FA9EFE Q27011203-B8CECEDA-5370-4D4C-8AA6-85FEDEC82A8D Q27320822-649FF56B-CD27-4A79-A8B9-3461BE93CCD8 Q27697984-12D643D6-C303-4623-9A0C-639EF27358C1 Q27924226-F794C002-0309-471E-9A72-B4C88EFBF94E Q28080225-D59B4FA0-6CD2-436F-9356-2B4E79379537 Q28485227-E9427025-74E4-4065-8D34-F5AD1105DE34 Q29994527-21332EF5-8B65-4137-AD2E-35FE3794EEEB Q30235178-F3F4B15F-5952-4F28-BAF3-61C7EB641367 Q32183060-6596B81E-9E44-4F59-B09D-DAE39B3267F9 Q33557819-AC89575A-11EE-4601-B24A-5D2CE4CB4D23 Q33798031-2ED34EB9-5D30-47EF-92F1-0D8D35B5B81D Q33798503-830C0398-5F98-44A3-987C-BE93274B11E1 Q33993178-27055A05-40A3-4AD8-BFE9-4C94DADDF212 Q34036018-31BA49DE-902C-440F-9854-BD283719180A Q34321440-8441CCC9-3902-4456-A4D3-8FF05E3907A1 Q34470890-A7FD15C8-20C6-4546-A863-9AA87FDC8E05 Q34548496-49CFC2A7-4513-4205-9DF3-724DDD47B33D Q35004972-19A1C32D-D2FA-48F7-8889-EB41209B1962 Q35103718-D2B4AD47-F4AD-419D-84AD-422067AD5BE7 Q35174673-E7BEBDB9-0C50-4806-BD74-F944CE6E1286 Q35907562-C7CD0103-CED7-433E-88F4-41F557A34B1A Q36084790-C729A233-510B-415F-8870-534A383E77E1 Q36290416-01FB3173-DBAE-47EE-9F8B-E7D6437A7DB8 Q36357128-A6A7E901-53C1-4060-8B94-546B13E55780 Q36438628-B0D97BDE-694F-49B2-9657-9D60EA34A75B Q36461735-EA246675-AA7F-4EA0-823D-78FC2E3D4387 Q36558549-8A50CAE8-51BF-4BE3-9FA4-0BCE47C05087 Q36579835-0ADEE137-79AA-4FEE-9A89-E089E8F70158 Q36667039-8D15A6DB-CFDF-4BB0-88A0-0C9D6BFA8448 Q36667165-F4F4500C-7BE2-4296-B5CD-082246D81E15

P2860

Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.

http://www.wikidata.org/entity/Q34623515

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Discovery of a β-d-2'-deoxy-2' ...... reatment of hepatitis C virus.

@ast

Discovery of a β-d-2'-deoxy-2' ...... reatment of hepatitis C virus.

@en

Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug

@nl

type

label

Discovery of a β-d-2'-deoxy-2' ...... reatment of hepatitis C virus.

@ast

Discovery of a β-d-2'-deoxy-2' ...... reatment of hepatitis C virus.

@en

Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug

@nl

prefLabel

Discovery of a β-d-2'-deoxy-2' ...... reatment of hepatitis C virus.

@ast

Discovery of a β-d-2'-deoxy-2' ...... reatment of hepatitis C virus.

@en

Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug

@nl

P1433

Q34623515-909C71B7-7EBE-4C15-9B03-69EEE8B2C87C

P1476

Q34623515-F2C33ACF-E7AF-494A-8CFD-1B59938CBE0C

P2093

Q34623515-00BDA157-5EE8-436C-8CB4-86322D299580

Q34623515-0EE0A6A1-08E1-42C6-9A1E-86450604B95F

Q34623515-194A637F-1EA2-4A23-A6E6-6AEA37C85EB2

Q34623515-24BC6BAF-21A8-4B2F-99D2-4C48DCB4D268

Q34623515-36BD19D5-D90F-4A7B-8D05-B89FD99B4D76

Q34623515-5505F076-51A7-45E4-9C40-5B7423CEAF78

Q34623515-5C5FC873-CDA7-4466-A891-A5F7093662F6

Q34623515-7DFE0304-3F0E-4056-8049-4F4E346B0D9A

Q34623515-8DAF7086-B173-49E3-8D64-A56F08AF07FA

Q34623515-8EB6DD17-3433-496F-B7C7-603401E5F1F1

P304

Q34623515-9EC4C7D6-483C-4EA8-B631-B887C00BA591

P31

Q34623515-4DF6C09C-04F0-4751-A251-9C5BA10BDDCD

P356

Q34623515-04E92817-D6BE-422D-BEC7-BE90F3CCABAD

P407

Q34623515-E50E898A-18D4-48AF-8A26-60F92AFFBB1E

P433

Q34623515-1D36149F-43C7-4E1F-87C2-CB92605724C1

P478

Q34623515-67B1A478-D7AF-4E54-A5B2-34482E79F0EF

P577

Q34623515-35B0A7DD-854F-4190-BC1E-20885CEB8658

P698

Q34623515-49AF119A-C004-421D-8CED-E75DE32E71FD

P356

P1433

Journal of Medicinal Chemistry

P1476

Discovery of a β-d-2'-deoxy-2' ...... reatment of hepatitis C virus.

@en

P2093

Angela M Lam

http://www.w3.org/2001/XMLSchema#string

Bruce S Ross

http://www.w3.org/2001/XMLSchema#string

Christine Espiritu

http://www.w3.org/2001/XMLSchema#string

Congrong Niu

http://www.w3.org/2001/XMLSchema#string

Dhanapalan Nagarathnam

http://www.w3.org/2001/XMLSchema#string

Donghui Bao

http://www.w3.org/2001/XMLSchema#string

Hai-Ren Zhang

http://www.w3.org/2001/XMLSchema#string

Holly M Micolochick Steuer

http://www.w3.org/2001/XMLSchema#string

Jinfa Du

http://www.w3.org/2001/XMLSchema#string

Meg Keilman

http://www.w3.org/2001/XMLSchema#string

P304

7202-7218

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM100863X

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20845908

http://www.w3.org/2001/XMLSchema#string